VanEck Gold Miners ETF vs NeoGenomics Inc. Common Stock — how do they compare? VanEck Gold Miners ETF trades at $85.08 (market cap $26.33B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B). The key difference: VanEck Gold Miners ETF is far larger — about 12.1× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| GDX | NEO | |
|---|---|---|
Market Cap | $26.33B | $2.17B |
Volume | 31,283,423 | 1,615,943 |
52-Week High | $115.84 | $19.91 |
52-Week Low | $68.28 | $7.19 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.47B |
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% over the past day, with a neutral technical signal and bearish moving averages. Key support is at $87, with resistance at $89. Financial ratios are unavailable, but recent news highlights institutional selling and comparisons between gold miners and physical gold ETFs. The fund's performance is influenced by gold prices and interest rate trends.
Outlook remains mixed amid gold price volatility and rising rates. Opportunities include potential catch-up if gold rallies, but risks involve further institutional outflows and macroeconomic pressure on metals. Investor sentiment is cautious, with technicals suggesting limited near-term momentum.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →